메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

The Reformer: How Sara Lamsam Transformed Muang Thai…

BANGKOK, Nov. 13, 2025 -- The journey of Mr. Sara Lamsam, CEO of Muang Thai Life Assurance (MTL), is a testament to the power of fusing strategic leadership with digital innovation. His success has been recognized with the Master Entrepreneur Award at the Asia Pacific Enterprise Awards (APEA) Thailand organised by Enterprise Asia, while his transformative work at the company earned MTL the Corporate Excellence Award. With over 32 years of experience and a strong belief in continuous self-development, Sara has spent his career modernizing the insurance industry. He spearheaded the cruci
- 김갑성 기자
- 2025-11-13 18:06
Clarivate Companies to Watch Report Spotlights Seven Women…

Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health LONDON, Nov. 13, 2025 -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its latest Companies to Watch report, Rediscovering Women's Health, highlighting seven companies driving innovation across reproductive care, chronic disease and mental health. Drawing on proprietary data, expert analysis and insights into therapeutic impact, financing activity and R&D momentum, the report showca
- 김갑성 기자
- 2025-11-13 16:00
Project ACTIVE 2.0 Strengthens Global Collaboration to Advanc…

CHIANG MAI, Thailand, Nov. 13, 2025 -- A major step forward in regional collaboration for cancer care was announced today with the launch of Project ACTIVE 2.0 (Advancing Cervical Cancer Treatment & Patient Recovery Across Southeast Asia), a multi-country initiative that aims to strengthen radiation oncology services and improve outcomes for cervical cancer across Southeast Asia. This effort is backed by the German Federal Ministry of Economic Cooperation and Development - BMZ, DEG Impulse, the Embassy of the Federal Republic of Germany in Bangkok, Elekta, and the Federatio
- 김갑성 기자
- 2025-11-13 15:40
KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefin…

XI'AN, China, Nov. 13, 2025 -- Guangzhou Focus Biotechnology Co., Ltd., a subsidiary of KHB Group and an innovator in veterinary point-of-care testing (POCT) solutions, presents the enhanced FOCUS PEGASUS MF200 Automatic Multifunctional Veterinary Analyzer — a next-generation system that redefines efficiency, reliability, and accessibility in veterinary diagnostics. The MF200 integrates Biochemistry, Electrolytes, Coagulation, and Immunofluorescence testing into one compact analyzer — delivering smart point-of-care diagnostics that meet the demands of modern veterinary practice
- 김갑성 기자
- 2025-11-13 15:18
Robert Lewandowski Named Global Brand Ambassador for K…

FC Barcelona Striker Partners with Most Clinically Researched Ashwagandha Brand, KSM-66 LOS ANGELES, Nov. 13, 2025 -- KSM-66®, one of the world's largest natural product ingredient brands and best-selling ashwagandha extract, today announced Robert Lewandowski as its global brand ambassador. The FC Barcelona striker and Poland captain will represent the brand worldwide across all markets where KSM-66 operates. The partnership pairs Lewandowski's two-decade career at football's elite level with KSM-66 Ashwagandha's commitment to 4000 year old Ayurvedic traditi
- 김갑성 기자
- 2025-11-13 15:00
Travelers from Singapore Can Now Access 24/7 Multilingual O…

TOKYO, Nov. 13, 2025 -- HOTEL de DOCTOR 24, a specialized online medical consultation service provided by M3 Career, Inc., offers seamless 24-hour access to healthcare for international travelers facing difficulties obtaining medical care in Japan. While HOTEL de DOCTOR 24 has been available in Japan since April 2025 -- and already used by travelers from Singapore -- this marks the first official introduction of the service to the Singapore market, ensuring that future visitors can access trusted medical support during their stay in Japan. Image: https://cdn.kyodonewsprwire.jp/prwfile/
- 김갑성 기자
- 2025-11-13 15:00
Agilent and National Heart Centre Singapore Sign Agreement…

[ 메디채널 김갑성 기자 ] Research focuses on human cardiac organoids to uncover metabolic drivers of heart failure and accelerate new therapeutic strategies to improve cardiovascular outcomes SINGAPORE, Nov. 13, 2025 -- Agilent Technologies Inc. (NYSE: A) announced the signing of a five-year Memorandum of Understanding (MOU) with National Heart Centre Singapore (NHCS) to accelerate innovation in metabolic heart failure research, one of the most complex and underserved areas in cardiovascular medicine. Agilent Seahorse XF Flex Analyzer 3D Workflow Features Metabolic Profile
- 김갑성 기자
- 2025-11-13 12:05
Medical AI Company VUNO Reports Profit in Q3, Driven by DeepCAR…

[ 메디채널 김갑성 기자 ] - 11 Consecutive Quarters of Revenue Growth; Q3 Revenue Exceeds KRW 10 billion for the First Time SEOUL, South Korea, Nov. 13, 2025 -- VUNO Inc., a global medical AI company, announced that it was profitable in the third quarter of 2025, recording consolidated revenue of KRW 10.8 billion, operating profit of KRW 1.0 billion, and net profit of KRW 1.0 billion. Revenue rose approximately 58% year-on-year (YoY) from KRW 6.9 billion in the same period last year and 17% quarter-on-quarter (QoQ) from KRW 9.3 billion in Q2. With this, VUNO has achieved 11 consecutive
- 김갑성 기자
- 2025-11-13 09:47
Ascletis Announces Co-formulation of ASC36, Once-Monthly N…

- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human primate studies. - ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 monotherapy
- 김갑성 기자
- 2025-11-13 07:30
Laronix Secures $3.2 Million Grant from the Australian Governm…

BRISBANE, Australia, Nov. 13, 2025 -- Laronix, ("Laronix" or the "Company"), a commercial-stage medical technology (MedTech) company and an industry-leading innovator in voice restoration technologies, today announced that it has been awarded AUD $3.2 million (approximately USD $2.1 million) in non-dilutive funding from the Australian Government's Industry Growth Program (IGP 2025). Farzaneh Ahmadi, PhD, Chief Executive Officer of Laronix, said, "Human voice loss is a largely unattended global health problem afflicting millions of patients every year. L
- 김갑성 기자
- 2025-11-13 06:30

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 02월 01일 00시 50분